N-linked glycosylation is one of the most frequent post-translational modifications of proteins with a profound impact on their biological function. Besides other functions, N-linked glycosylation assists in protein folding, determines protein orientation at the cell surface, or protects proteins from proteases. The N-linked glycans attach to asparagines in the sequence context Asn-X-Ser/Thr, where X is any amino acid except proline. Any variation (e.g. non-synonymous single nucleotide polymorphism or mutation) that abolishes the N-glycosylation sequence motif will lead to the loss of a glycosylation site. On the other hand, variations causing a substitution that creates a new N-glycosylation sequence motif can result in the gain of glycosylation. Although the general importance of glycosylation is well known and acknowledged, the effect of variation on the actual glycoproteome of an organism is still mostly unknown. In this study, we focus on a comprehensive analysis of non-synonymous single nucleotide variations (nsSNV) that lead to either loss or gain of the N-glycosylation motif. We find that 1091 proteins have modified N-glycosylation sequons due to nsSNVs in the genome. Based on analysis of proteins that have a solved 3D structure at the site of variation, we find that 48% of the variations that lead to changes in glycosylation sites occur at the loop and bend regions of the proteins. Pathway and function enrichment analysis show that a significant number of proteins that gained or lost the glycosylation motif are involved in kinase activity, immune response, and blood coagulation. A structure-function analysis of a blood coagulation protein, antithrombin III and a protease, cathepsin D, showcases how a comprehensive study followed by structural analysis can help better understand the functional impact of the nsSNVs.
References
[1]
Boscher C, Dennis JW, Nabi IR (2011) Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol 23: 383–392.
[2]
Dall'olio F (1996) Protein glycosylation in cancer biology: an overview. Clin Mol Pathol 49: M126–135.
[3]
Dennis JW, Nabi IR, Demetriou M (2009) Metabolism, cell surface organization, and disease. Cell 139: 1229–1241.
[4]
Dwek RA (1996) Glycobiology: Toward Understanding the Function of Sugars. Chem Rev 96: 683–720.
Marino K, Bones J, Kattla JJ, Rudd PM (2010) A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol 6: 713–723.
[7]
Peracaula R, Barrabes S, Sarrats A, Rudd PM, de Llorens R (2008) Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers 25: 207–218.
[8]
Pless DD, Lennarz WJ (1977) Enzymatic conversion of proteins to glycoproteins. Proc Natl Acad Sci U S A 74: 134–138.
[9]
Zielinska DF, Gnad F, Wisniewski JR, Mann M (2010) Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell 141: 897–907.
[10]
Haeuptle MA, Hennet T (2009) Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides. Hum Mutat 30: 1628–1641.
[11]
Zhao YY, Takahashi M, Gu JG, Miyoshi E, Matsumoto A, et al. (2008) Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci 99: 1304–1310.
[12]
Varki A, Kannagi R, Toole BP (2009) Glycosylation Changes in Cancer.
[13]
Mkhikian H, Grigorian A, Li CF, Chen HL, Newton B, et al. (2011) Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun 2: 334.
[14]
Vogt G, Vogt B, Chuzhanova N, Julenius K, Cooper DN, et al. (2007) Gain-of-glycosylation mutations. Curr Opin Genet Dev 17: 245–251.
[15]
Vogt G, Chapgier A, Yang K, Chuzhanova N, Feinberg J, et al. (2005) Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet 37: 692–700.
[16]
Klein A (2008) Human total serum N-glycome. Adv Clin Chem 46: 51–85.
[17]
Alavi A, Axford JS (2008) Sweet and sour: the impact of sugars on disease. Rheumatology (Oxford) 47: 760–770.
[18]
Ohtsubo K, Marth JD (2006) Glycosylation in cellular mechanisms of health and disease. Cell 126: 855–867.
[19]
Li S, Iakoucheva LM, Mooney SD, Radivojac P (2009) Loss of post-translational modification sites in disease. Pac Symp Biocomput. pp. 337–347.
[20]
Waite A, De Rosa MC, Brancaccio A, Blake DJ (2011) A gain-of-glycosylation mutation associated with myoclonus-dystonia syndrome affects trafficking and processing of mouse epsilon-sarcoglycan in the late secretory pathway. Hum Mutat 32: 1246–1258.
[21]
Firth SM, Yan X, Baxter RC (2010) D440N mutation in the acid-labile subunit of insulin-like growth factor complexes inhibits secretion and complex formation. Mol Endocrinol 25: 307–314.
[22]
Roll P, Rudolf G, Pereira S, Royer B, Scheffer IE, et al. (2006) SRPX2 mutations in disorders of language cortex and cognition. Hum Mol Genet 15: 1195–1207.
[23]
Kretz KA, Carson GS, Morimoto S, Kishimoto Y, Fluharty AL, et al. (1990) Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect. Proc Natl Acad Sci U S A 87: 2541–2544.
[24]
Park C, Zhang J (2011) Genome-wide evolutionary conservation of N-glycosylation sites. Mol Biol Evol 28: 2351–2357.
[25]
Freeze HH, Westphal V (2001) Balancing N-linked glycosylation to avoid disease. Biochimie 83: 791–799.
[26]
Costantino L, Catalano MG, Frairia R, Carmazzi CM, Barbero M, et al. (2009) Molecular mechanisms of the D327N SHBG protective role on breast cancer development after estrogen exposure. Breast Cancer Res Treat 114: 449–456.
[27]
Cui Y, Shu XO, Cai Q, Jin F, Cheng JR, et al. (2005) Association of breast cancer risk with a common functional polymorphism (Asp327Asn) in the sex hormone-binding globulin gene. Cancer Epidemiol Biomarkers Prev 14: 1096–1101.
[28]
Raineri M, Catalano MG, Hammond GL, Avvakumov GV, Frairia R, et al. (2002) O-Glycosylation of human sex hormone-binding globulin is essential for inhibition of estradiol-induced MCF-7 breast cancer cell proliferation. Mol Cell Endocrinol 189: 135–143.
[29]
UniProt C (2010) Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res 39: D214–219.
[30]
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248–249.
[31]
Small I, Peeters N, Legeai F, Lurin C (2004) Predotar: A tool for rapidly screening proteomes for N-terminal targeting sequences. Proteomics 4: 1581–1590.
[32]
Mi H, Thomas P (2009) PANTHER pathway: an ontology-based pathway database coupled with data analysis tools. Methods Mol Biol 563: 123–140.
[33]
Ahmad S, Gromiha M, Fawareh H, Sarai A (2004) ASAView: database and tool for solvent accessibility representation in proteins. BMC Bioinformatics 5: 51.
[34]
Sayers EW, Barrett T, Benson DA, Bolton E, Bryant SH, et al. (2009) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 38: D5–16.
[35]
Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308–311.
[36]
Zhang H, Li XJ, Martin DB, Aebersold R (2003) Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 21: 660–666.
[37]
Brumshtein B, Wormald MR, Silman I, Futerman AH, Sussman JL (2006) Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease. Acta Crystallogr D Biol Crystallogr 62: 1458–1465.
[38]
Bunkenborg J, Pilch BJ, Podtelejnikov AV, Wisniewski JR (2004) Screening for N-glycosylated proteins by liquid chromatography mass spectrometry. Proteomics 4: 454–465.
[39]
Liu T, Qian WJ, Gritsenko MA, Camp DG , Monroe ME, et al. (2005) Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res 4: 2070–2080.
[40]
Nilsson J, Ruetschi U, Halim A, Hesse C, Carlsohn E, et al. (2009) Enrichment of glycopeptides for glycan structure and attachment site identification. Nat Methods 6: 809–811.
[41]
Windpassinger C, Auer-Grumbach M, Irobi J, Patel H, Petek E, et al. (2004) Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet 36: 271–276.
[42]
Ohnishi T, Muroi M, Tanamoto K (2003) MD-2 is necessary for the toll-like receptor 4 protein to undergo glycosylation essential for its translocation to the cell surface. Clin Diagn Lab Immunol 10: 405–410.
[43]
Ohnishi T, Muroi M, Tanamoto K (2001) N-linked glycosylations at Asn(26) and Asn(114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappaB by lipopolysaccharide. J Immunol 167: 3354–3359.
[44]
Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: 172–187.
[45]
Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS (2008) Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res 68: 3803–3809.
[46]
Kobata A (2000) A journey to the world of glycobiology. Glycoconj J 17: 443–464.
[47]
Davie EW, Fujikawa K, Kisiel W (1991) The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30: 10363–10370.
[48]
Okamoto N, Wada Y, Kobayashi M, Otani K, Tagawa T, et al. (1993) Decreased blood coagulation activities in carbohydrate-deficient glycoprotein syndrome. J Inherit Metab Dis 16: 435–440.
[49]
Wheatley M, Hawtin SR (1999) Glycosylation of G-protein-coupled receptors for hormones central to normal reproductive functioning: its occurrence and role. Hum Reprod Update 5: 356–364.
[50]
Kimber SJ (2000) Molecular interactions at the maternal-embryonic interface during the early phase of implantation. Semin Reprod Med 18: 237–253.
[51]
Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153–158.
[52]
Bagriacik EU, Kirkpatrick A, Miller KS (1996) Glycosylation of native MHC class Ia molecules is required for recognition by allogeneic cytotoxic T lymphocytes. Glycobiology 6: 413–421.
[53]
Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA (2001) Glycosylation and the immune system. Science 291: 2370–2376.
[54]
Heutinck KM, ten Berge IJ, Hack CE, Hamann J, Rowshani AT (2010) Serine proteases of the human immune system in health and disease. Mol Immunol 47: 1943–1955.
[55]
Hino M, Kijima-Suda I, Nagai Y, Hosoya H (2003) Glycosylation of the alpha and beta tubulin by sialyloligosaccharides. Zoolog Sci 20: 709–715.
[56]
Vandenborre G, Smagghe G, Ghesquiere B, Menschaert G, Nagender Rao R, et al. (2011) Diversity in protein glycosylation among insect species. PLoS One 6: e16682.
[57]
Dutta S, Zardecki C, Goodsell DS, Berman HM (2010) Promoting a structural view of biology for varied audiences: an overview of RCSB PDB resources and experiences. J Appl Crystallogr 43: 1224–1229.
[58]
Avanov A (1991) Conformational aspects of glycosylation. Mol Biol (Mosk) 25: 293–308.
[59]
Imberty A, Perez S (1995) Stereochemistry of the N-glycosylation sites in glycoproteins. Protein Eng 8: 699–709.
[60]
Petrescu AJ, Milac AL, Petrescu SM, Dwek RA, Wormald MR (2004) Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. Glycobiology 14: 103–114.
[61]
Horton P, Park KJ, Obayashi T, Fujita N, Harada H, et al. (2007) WoLF PSORT: protein localization predictor. Nucleic Acids Res. 35 (Web Server issue). pp. W585–587.
[62]
Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, et al. (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39: D561–568.
[63]
Tyler-Cross R, Sobel M, Marques D, Harris RB (1994) Heparin binding domain peptides of antithrombin III: analysis by isothermal titration calorimetry and circular dichroism spectroscopy. Protein Sci 3: 620–627.
[64]
Bayston TA, Tripodi A, Mannucci PM, Thompson E, Ireland H, et al. (1999) Familial overexpression of beta antithrombin caused by an Asn135Thr substitution. Blood 93: 4242–4247.
[65]
Masson O, Bach AS, Derocq D, Prebois C, Laurent-Matha V, et al. (2010) Pathophysiological functions of cathepsin D: Targeting its catalytic activity versus its protein binding activity? Biochimie 92: 1635–1643.
[66]
Fortenberry SC, Schorey JS, Chirgwin JM (1995) Role of glycosylation in the expression of human procathepsin D. J Cell Sci 108 (Pt 5): 2001–2006.
